|
February 9, 2012
|
| 09:54 EDT |  | ILMN |
| theflyonthewall.com: | Rumor: Illumina moves up on chatter of activist investor interest | | :theflyonthewall.com |
|
| 08:58 EDT |  | ILMN |
| theflyonthewall.com: | Illumina management to meet with JP Morgan | | Meetings to be held in New York on February 13 and in Baltimore on February 14 hosted by JP Morgan. :theflyonthewall.com |
|
|
February 8, 2012
|
| 16:20 EDT |  | ILMN |
|
| 05:31 EDT | | ILMN |
|
|
February 7, 2012
|
| 16:20 EDT | | ILMN |
|
| 16:17 EDT |  | ILMN |
|
| 16:16 EDT | | ILMN |
|
| 16:14 EDT | | ILMN |
|
|
February 3, 2012
|
| 11:26 EDT | | ILMN |
|
| 11:25 EDT | | ILMN |
|
|
February 2, 2012
|
| 09:16 EDT |  | ILMN |
|
|
February 1, 2012
|
| 06:58 EDT |  | ILMN |
|
|
January 31, 2012
|
| 15:58 EDT | | ILMN |
|
| 12:06 EDT | | ILMN |
| theflyonthewall.com: | Roche to nominate slate of candidates to Illumina board | | Roche (RHHBY) announced that it has provided notice to Illumina (ILMN) that it will nominate a slate of independent candidates for election to Illumina’s board and propose certain other matters for the consideration of Illumina’s shareholders at Illumina’s 2012 annual meeting, which, if adopted, would result in Roche-nominated directors comprising a majority of the Illumina board. Roche also named five alternate nominees for election to Illumina’s board. Roche will also propose increasing the size of Illumina’s board from nine directors to eleven directors with the resulting vacancies on the board to be filled by candidates nominated by Roche. :theflyonthewall.com |
|
| 06:57 EDT | | ILMN |
|
|
January 27, 2012
|
| 11:54 EDT | | ILMN |
|
| 10:17 EDT | | ILMN |
| theflyonthewall.com: | Illumina reaffirms Q4 preliminary results, postpones earnings announcement | | Illumina reaffirmed the preliminary unaudited Q4 fiscal year financial results disclosed on January 10, including Q4 revenue of approximately $250M and EPS of 34c per share. Also as disclosed previously, the company reaffirmed its expectation that it will meet or exceed equity analyst estimates for 2012 and will resume providing guidance on its Q4 earnings call. In light of the commencement of Roche’s unsolicited tender offer, Illumina announced that it will postpone its previously scheduled Q4 and fiscal earnings announcement. The company expects to issue results concurrent with the board’s completion of its review of Roche’s unsolicited tender offer and the issue of its recommendation. :theflyonthewall.com |
|
| 10:14 EDT | | ILMN |
|
| 06:48 EDT | | ILMN |
|
|
January 26, 2012
|
| 07:39 EDT |  | ILMN |
| theflyonthewall.com: | Illumina likely to be acquired by Roche, says Oppenheimer | | Oppenheimer expects Roche's (RHHBY) hostile bid for Illumina (ILMN) to ultimately be successful, and the firm would not be surprised to see Roche's current offer price of $44.50 increase. However, the firm views the offer price as rather high and maintains a Perform rating on illumina. :theflyonthewall.com |
|
| 07:28 EDT |  | ILMN |
| theflyonthewall.com: | J&J could make cash offer for Elan sparked by Roche/Illumina, Daily Mail says | | Following Roche's (RHHBY) bid for Illumina (ILMN), rumors are swirling that Johnson & Johnson (JNJ) could pounce on Elan (ELN) with a "knock-out" cash offer, the Daily Mail reports. Johnson & Johnson holds an 18% stake in Elan. Reference Link :theflyonthewall.com |
|
| 07:06 EDT | | ILMN |
|
| 07:03 EDT | | ILMN |
| theflyonthewall.com: | Loophole gives Roche chance to win Illumina proxy battle in 2012, NY Times says |
 Subscribe for More Information :theflyonthewall.com |
|
| 06:49 EDT | | ILMN |
|
| 06:34 EDT | | ILMN |
| theflyonthewall.com: | Illumina adopts stockholder rights agreement | | Illumina (ILMN) announced that its Board of Directors adopted a Rights Agreement, pursuant to which one preferred stock purchase right will be distributed as a dividend on each share of the Company’s common stock held of record as of the close of business on February 6. The Rights Agreement, which is designed to deter coercive or otherwise unfair takeover tactics, was adopted in response to the announcement by Roche (RHHBY) of its unsolicited acquisition proposal to acquire all of the outstanding shares of Illumina’s common stock for $44.50 per share in cash. Under the Rights Agreement, with certain exceptions, if any person or group becomes the beneficial owner of 15% or more of the Company’s common stock, then each Right not beneficially owned by such beneficial owner will entitle its holder to purchase, at the Rights’ then-current exercise price, shares of the Company’s common stock having a market value of twice the Rights’ then-current exercise price. :theflyonthewall.com |
|
